Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence

Neurodegener Dis Manag. 2019 Apr;9(2s):1-2. doi: 10.2217/nmt-2018-0048. Epub 2019 Jan 18.

Abstract

Proceedings of an Almirall-sponsored satellite symposium held at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Berlin, Germany, 10 October 2018.

Keywords: THC:CBD oromucosal spray; multiple sclerosis spasticity treatment; observational studies; randomized controlled trials.

MeSH terms

  • Administration, Mucosal
  • Cannabidiol / administration & dosage
  • Cannabidiol / pharmacology*
  • Cannabinoid Receptor Modulators / administration & dosage
  • Cannabinoid Receptor Modulators / pharmacology*
  • Congresses as Topic*
  • Dronabinol / administration & dosage
  • Dronabinol / pharmacology*
  • Drug Combinations
  • Humans
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / drug therapy*
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / etiology
  • Observational Studies as Topic*
  • Oral Sprays
  • Randomized Controlled Trials as Topic*
  • Societies, Medical

Substances

  • Cannabinoid Receptor Modulators
  • Drug Combinations
  • Oral Sprays
  • Cannabidiol
  • Dronabinol
  • nabiximols